Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Surein Arulananda, Ph.D., M.B.,B.S.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Arulananda S, O'Brien M, Evangelista M, Harris TJ, Steinohrt NS, Jenkins LJ, Walkiewicz M, O'Donoghue RJJ, Poh AR, Thapa B, Williams DS, Leong T, Mariadason JM, Li X, Cebon J, Lee EF, John T, Fairlie WD. Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discov. 2021 Jun 15; 7(1):146. PMID: 34131107.
  2. Arulananda S, O'Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M, Leong T, Mariadason JM, Cebon J, Balachander SB, Cidado JR, Lee EF, John T, Fairlie WD. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 2021 May 28; 7(1):122. PMID: 34050131.
    Citations: 1     
  3. Arulananda S, Lee EF, Fairlie WD, John T. The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2021 04; 21(4):413-424. PMID: 33238762.
    Citations: 2     Fields:    
  4. Arulananda S, O'Brien M, Evangelista M, Harris TJ, Steinohrt NS, Jenkins LJ, Walkiewicz M, O'Donoghue RJJ, Poh AR, Thapa B, Williams DS, Leong T, Mariadason JM, Li X, Cebon J, Lee EF, John T, Fairlie WD. BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discov. 2020 Oct 31; 6(1):114. PMID: 33298868.
    Citations: 5     
  5. Arulananda S, John T. Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer-ready for prime time? Transl Lung Cancer Res. 2020 Oct; 9(5):1728-1731. PMID: 33209595.
  6. Lie G, Weickhardt A, Kearney L, Lam Q, John T, Liew D, Arulananda S. Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. Transl Lung Cancer Res. 2020 Apr; 9(2):360-365. PMID: 32420076.
    Citations: 2     
  7. Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, Luo S, Lahn M, Kallender H, Mannucci A, Somma C, Woods K, Behren A, Fernandez-Penas P, Millward M, Meniawy T. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther. 2020; 14:1177-1189. PMID: 32256049.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  8. Zheng Y, Zhou M, Arulananda S, Um SW, Li H. Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion. J Thorac Dis. 2020 Mar; 12(3):159-164. PMID: 32274080.
  9. Arulananda S, John T. Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush? J Thorac Oncol. 2020 01; 15(1):12-14. PMID: 31864546.
    Citations:    Fields:    Translation:Humans
  10. Loh Z, Mitchell P, John T, Arulananda S. RET-rearranged non-small-cell lung cancer and therapeutic implications. Intern Med J. 2019 12; 49(12):1541-1545. PMID: 31808254.
    Citations: 2     Fields:    Translation:Humans
  11. Gunjur A, Chong G, Lim A, Lau E, Mitchell P, John T, Arulananda S. Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report. Clin Lung Cancer. 2020 03; 21(2):e57-e60. PMID: 31864906.
    Citations: 1     Fields:    Translation:Humans
  12. Arulananda S, Mitchell P, John T. DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it? J Thorac Oncol. 2019 09; 14(9):1498-1500. PMID: 31445727.
    Citations: 1     Fields:    Translation:Humans
  13. Arulananda S, Parakh S, Palmer J, Goodwin M, Andrews MC, Cebon J. A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. Cancer Rep (Hoboken). 2019 08; 2(4):e1183. PMID: 32721131.
    Citations: 3     Translation:HumansCTClinical Trials
  14. Arulananda S, Do H, Rivalland G, Loh Z, Musafer A, Lau E, Mitchell P, Dobrovic A, John T. Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. J Thorac Dis. 2019 May; 11(5):1756-1764. PMID: 31285867.
    Citations: 3     
  15. Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, Ramnac C, Hobbs C, Zhu H, Gunasingh G, Segal D, Behren A, Cebon J, Dobrovic A, Mariadason JM, Strasser A, Rohrbeck L, Haass NK, Herold MJ, Fairlie WD. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019 04 24; 10(5):342. PMID: 31019203.
    Citations: 36     Fields:    Translation:HumansCells
  16. Arulananda S, Mitchell P. Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold. Transl Lung Cancer Res. 2018 Dec; 7(Suppl 4):S388-S392. PMID: 30705864.
    Citations: 1     
  17. Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. Eur J Cancer. 2018 12; 105:88-102. PMID: 30439628.
    Citations: 13     Fields:    Translation:Humans
  18. Arulananda S, Lynam J, Sem Liew M, Wada M, Cher L, Gan HK. Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients. Intern Med J. 2018 Oct; 48(10):1206-1214. PMID: 29923272.
    Citations: 1     Fields:    Translation:Humans
  19. Arulananda S, Thapa B, Walkiewicz M, Zapparoli GV, Williams DS, Dobrovic A, John T. Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018 10; 13(10):1588-1594. PMID: 30056163.
    Citations: 9     Fields:    Translation:Humans
  20. Arulananda S, Mitchell P. BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC? J Thorac Oncol. 2018 08; 13(8):1055-1057. PMID: 30056857.
    Citations:    Fields:    Translation:Humans
  21. Do H, Arulananda S, John T, Dobrovic A. In Reply to Leone. J Thorac Oncol. 2018 02; 13(2):e22-e23. PMID: 29425615.
    Citations:    Fields:    Translation:Humans
  22. Arulananda S, Do H, Musafer A, Mitchell P, Dobrovic A, John T. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 11; 12(11):1728-1732. PMID: 28843359.
    Citations: 42     Fields:    Translation:Humans
  23. Arulananda S, John T. The ADAM Trial: Visiting the Road Less Traveled. JAMA Oncol. 2017 01 01; 3(1):66-67. PMID: 27584157.
    Citations:    Fields:    Translation:Humans
  24. Arulananda S, Rivalland G, John T. Combination approaches in NSCLC involving immune checkpoint inhibitors. Lung Cancer Manag. 2016 Dec; 5(4):163-171. PMID: 30643561.
  25. Arulananda S, Liew MS, Battye S, McDonald CF, Mitchell P. Pulmonary metastases: a rare manifestation of the most common cancer. Australas J Dermatol. 2013 Aug; 54(3):e70-3. PMID: 22672019.
    Citations:    Fields:    Translation:Humans
  26. Sem Liew M, Arulananda S, Seow J, Mitchell P, John T. Bronchoepidural Fistula in a man with actinomycosis complicated non-small cell lung cancer. J Thorac Oncol. 2011 Oct; 6(10):1761-2. PMID: 21918391.
    Citations: 1     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Arulananda's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (90)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.